Use access key #2 to skip to page content.

Closing MEDX (Medarex) underperform

Recs

1

April 02, 2008 – Comments (0) | RELATED TICKERS: MEDX

I think at this point all value related to Ipilimumab and related compounds can be written off. However, the  company still has substantial assets related to its monoclonal antibody platform which are difficult to valuate and could generate upward stock mobility in the near future.

0 Comments – Post Your Own

Featured Broker Partners


Advertisement